Jennifer A. Doudna is a distinguished American biochemist and a seminal figure in modern genetics, renowned for her pioneering work in the development of CRISPR-Cas9 genome-editing technology. Born on February 19, 1964, in Washington, D.C., and raised primarily in Hilo, Hawaii, Doudna developed an early interest in science, influenced by her father’s academic background in literature and her mother’s work in history, alongside her own childhood fascination with the lush, diverse ecosystem of Hawaii. She pursued her undergraduate studies at Pomona College, where she earned a Bachelor of Arts in chemistry in 1985. She continued her academic journey at Harvard Medical School, completing her Ph.D. in biological chemistry and molecular pharmacology in 1989 under the mentorship of Jack Szostak. Following her doctoral studies, she conducted postdoctoral research at the University of Colorado Boulder under Thomas Cech, where she focused on the structure and function of RNA enzymes. Doudna’s academic career is marked by significant contributions to structural biology, particularly concerning RNA molecules. Before her breakthrough with CRISPR, she held faculty positions at Yale University and subsequently joined the University of California, Berkeley, in 2002. It was at UC Berkeley that her laboratory delved into the molecular mechanisms of RNA interference and eventually the bacterial immune system known as CRISPR-Cas9. In 2012, Doudna, in collaboration with French microbiologist Emmanuelle Charpentier, published a landmark study in the journal Science. This research demonstrated that the CRISPR-Cas9 system, originally a bacterial defense mechanism against viruses, could be repurposed into a programmable tool for precise genome editing in any organism. This discovery revolutionized the field of biotechnology, providing scientists with an efficient, affordable, and versatile method to alter DNA sequences, thereby opening new frontiers in medicine, agriculture, and basic biological research. The global impact of Doudna’s work has been recognized with numerous prestigious honors. In 2020, Doudna and Charpentier were awarded the Nobel Prize in Chemistry for their development of the CRISPR-Cas9 method, becoming the first two women to share the prize in chemistry. Beyond the Nobel, Doudna is a recipient of the Breakthrough Prize in Life Sciences, the Gruber Prize in Genetics, and the Japan Prize, among others. She is an elected member of the National Academy of Sciences and the American Academy of Arts and Sciences. Throughout her career, Doudna has been a vocal advocate for the responsible use of gene-editing technologies. She has frequently called for rigorous ethical oversight and public dialogue regarding the potential applications of CRISPR, particularly in human germline editing. As the Li Ka Shing Chancellor’s Chair and a professor in the Departments of Chemistry and of Molecular and Cell Biology at UC Berkeley, she continues to lead research into the future of genomics. She also serves as the president and chair of the Innovative Genomics Institute, a collaborative research organization she founded to translate academic discoveries into real-world applications. Personally, Doudna is married to fellow researcher Jamie Cate, and they have one son. Her work remains a cornerstone of 21st-century science, fundamentally altering the trajectory of medical research and the ethics of genetic modification.